Tetraphase Pharmaceuticals (TTPH) Reaches New 12-Month Low at $1.70

Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $1.70 and last traded at $1.71, with a volume of 16463 shares traded. The stock had previously closed at $1.76.

TTPH has been the subject of a number of research analyst reports. Piper Jaffray Companies decreased their price objective on shares of Tetraphase Pharmaceuticals to $6.00 and set an “overweight” rating for the company in a report on Thursday, October 11th. WBB Securities upgraded shares of Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Thursday, September 6th. HC Wainwright raised their price objective on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Finally, B. Riley raised their price objective on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 28th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $6.16.

The firm has a market capitalization of $92.77 million, a PE ratio of -0.63 and a beta of 2.69.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $2.09 million. Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%. On average, research analysts anticipate that Tetraphase Pharmaceuticals Inc will post -1.32 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of TTPH. Flagship Harbor Advisors LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth about $104,000. Cubist Systematic Strategies LLC increased its stake in shares of Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 24,837 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth about $179,000. Alambic Investment Management L.P. increased its stake in shares of Tetraphase Pharmaceuticals by 392.6% in the third quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 69,900 shares in the last quarter. Finally, Bridgeway Capital Management Inc. increased its stake in shares of Tetraphase Pharmaceuticals by 131.6% in the third quarter. Bridgeway Capital Management Inc. now owns 184,800 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 105,000 shares in the last quarter. Hedge funds and other institutional investors own 42.82% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Reaches New 12-Month Low at $1.70” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/12/08/tetraphase-pharmaceuticals-ttph-reaches-new-12-month-low-at-1-70.html.

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Return on Investment (ROI)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply